Baird's Outperform Rating for Alkermes Focused on Revenue Stream and ALKS 2680
Tuesday, 19 March 2024, 18:37
Baird initiates coverage of Alkermes with an outperform rating
Baird, a renowned financial institution, has recently initiated coverage of Alkermes (ALKS) with an outperform rating. The analysis highlighted the company's strong revenue stream and the potential of its narcolepsy drug candidate, ALKS 2680.
Focused on revenue potential
The rating emphasizes the promising revenue stream of Alkermes, indicating confidence in its financial performance and growth trajectory. This positive outlook positions Alkermes as a attractive investment opportunity in the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.